Association/NN
of/IN
an/DT
Anti-inflammatory/JJ
Cytokine/NN
Gene/NN
IL4/NN
Polymorphism/NN
with/IN
the/DT
Risk/NN
of/IN
Type/NN
2/CD
Diabetes/NNS
Mellitus/NN
in/IN
Korean/JJ
Populations/NNS
./.
====================
Chronic/JJ
inflammation/NN
has/VBZ
been/VBN
implicated/VBN
as/IN
one/CD
of/IN
the/DT
important/JJ
etiological/JJ
factors/NNS
in/IN
insulin/NN
resistance/NN
and/CC
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
./.
====================
To/TO
investigate/VB
the/DT
role/NN
of/IN
anti-inflammatory/JJ
cytokines/NNS
in/IN
the/DT
development/NN
of/IN
T2DM/NN
,/,
we/PRP
conducted/VBD
a/DT
case-control/JJ
study/NN
to/TO
assess/VB
the/DT
association/NN
between/IN
IL4/IL4R/NN
polymorphisms/NNS
and/CC
disease/NN
risk/NN
./.
====================
We/PRP
firstly/RB
identified/VBN
single/JJ
nucleotide/NN
polymorphisms/NNS
(/(
SNP/NN
)/)
at/IN
IL4/NN
and/CC
IL4RA/NN
loci/NNS
by/IN
sequencing/NN
the/DT
loci/NNS
in/IN
Korean/JJ
participants/NNS
./.
====================
Case-control/NN
studies/NNS
were/VBD
conducted/VBN
by/IN
genotyping/VBG
the/DT
SNPs/NNS
in/IN
474/CD
T2DM/NN
cases/NNS
and/CC
470/CD
non-diabetic/JJ
controls/NNS
recruited/VBN
from/IN
community-based/VBN
cohorts/NNS
./.
====================
Replication/NN
of/IN
the/DT
associated/VBN
signals/NNS
was/VBD
performed/VBN
in/IN
1,216/CD
cases/NNS
and/CC
1,352/CD
controls/NNS
./.
====================
We/PRP
assessed/VBD
effect/NN
of/IN
IL4-IL4RA/NN
interaction/NN
on/IN
T2DM/NN
using/VBG
logistic/JJ
regression/NN
method/NN
./.
====================
The/DT
functional/JJ
relevance/NN
of/IN
the/DT
SNP/NN
associated/VBN
with/IN
disease/NN
risk/NN
was/VBD
determined/VBN
using/VBG
a/DT
reporter/NN
expression/NN
assay/NN
./.
====================
We/PRP
identified/VBD
a/DT
strong/JJ
association/NN
between/IN
the/DT
IL4/NN
promoter/NN
variant/JJ
rs2243250/NN
and/CC
T2DM/NN
risk/NN
(/(
OR=0.77/NN
;/:
95/CD
%/NN
CI/NN
,/,
0.67∼0.88/CD
;/:
p=1.65×10－4/RB
in/IN
the/DT
meta-analysis/NN
)/)
./.
====================
The/DT
reporter/NN
gene/NN
expression/NN
assay/NN
demonstrated/VBD
that/IN
the/DT
presence/NN
of/IN
rs2243250/NN
might/MD
affect/VB
the/DT
gene/NN
expression/NN
level/NN
with/IN
∼1.5-fold/JJ
allele/NN
difference/NN
./.
====================
Our/PRP$
findings/NNS
contribute/VBP
to/TO
the/DT
identification/NN
of/IN
IL4/NN
as/IN
a/DT
T2D/NN
susceptibility/NN
locus/NN
,/,
further/RB
supporting/VBG
the/DT
role/NN
of/IN
antiinflammatory/JJ
cytokines/NNS
in/IN
T2DM/NN
disease/NN
development/NN
./.
====================
Keywords/NNS
:/:
type/NN
2/CD
diabetes/NNS
mellitus/NN
,/,
single/JJ
nucleotide/NN
polymorphisms/NNS
,/,
IL4/NN
,/,
IL4R/NN
,/,
anti-inflammatory/JJ
cytokine/NN
,/,
gene-gene/NN
interactionType/JJ
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
is/VBZ
one/CD
of/IN
the/DT
diseases/NNS
for/IN
which/WDT
the/DT
etiological/JJ
factors/NNS
have/VBP
been/VBN
revealed/VBN
by/IN
recent/JJ
progress/VBP
in/IN
genomewide/NN
association/NN
studies/NNS
(/(
GWAS/NN
)/)
./.
====================
More/RBR
than/IN
20/CD
genetic/JJ
loci/NNS
have/VBP
been/VBN
identified/VBN
as/IN
being/VBG
associated/VBN
with/IN
the/DT
risk/NN
of/IN
T2DM/NN
,/,
and/CC
this/DT
finding/NN
has/VBZ
been/VBN
replicated/VBN
across/IN
different/JJ
ethnic/JJ
populations/NNS
./.
====================
Many/JJ
of/IN
the/DT
loci/NNS
are/VBP
involved/VBN
in/IN
pancreatic/JJ
β/NN
cell/NN
function/NN
,/,
suggesting/VBG
the/DT
technical/JJ
validity/NN
of/IN
GWAS/NN
and/CC
predominant/JJ
contribution/NN
of/IN
these/DT
loci/NNS
to/TO
T2DM/NN
(/(
Prokopenko/NNP
et/FW
al./FW
,/,
2008/CD
)/)
./.
====================
However/RB
,/,
given/VBN
the/DT
genetic/JJ
heterogeneity/NN
of/IN
the/DT
disease/NN
,/,
hypothesisbased/VBN
candidate/NN
gene/NN
approaches/NNS
have/VBP
been/VBN
successfully/RB
applied/VBN
along/IN
with/IN
GWAS/NN
to/TO
identify/VB
additional/JJ
loci/NNS
that/IN
are/VBP
moderately/RB
associated/VBN
with/IN
T2DM/NN
./.
====================
Among/IN
the/DT
candidates/NNS
,/,
genes/NNS
involved/VBN
in/IN
inflammation/NN
have/VBP
been/VBN
intensively/RB
studied/VBN
,/,
with/IN
most/JJS
studies/NNS
examining/VBG
the/DT
role/NN
of/IN
subclinical/JJ
chronic/JJ
inflammation/NN
in/IN
the/DT
development/NN
of/IN
insulin/NN
resistance/NN
and/CC
T2DM/NN
(/(
Shoelson/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
It/PRP
is/VBZ
known/VBN
that/IN
chronic/JJ
overnutrition/JJ
results/NNS
in/IN
local/JJ
inflammation/NN
in/IN
adipose/JJ
tissue/NN
,/,
mediated/VBN
by/IN
macrophage/NN
infiltration/NN
and/CC
increased/VBD
production/NN
of/IN
proinflammatory/JJ
mediators/NNS
,/,
the/DT
occurrence/NN
of/IN
which/WDT
potentiates/VBZ
insulin/NN
resistance/NN
(/(
Weisberg/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Consistently/RB
,/,
genetic/JJ
variants/NNS
in/IN
proinflammatory/JJ
markers/NNS
and/CC
cytokines/NNS
have/VBP
been/VBN
tested/VBN
in/IN
many/JJ
studies/NNS
,/,
supported/VBD
by/IN
clinical/JJ
observation/NN
including/VBG
elevated/JJ
levels/NNS
of/IN
tumor/NN
necrosis/NN
factorα/JJ
(/(
TNFα/NNP
)/)
,/,
Creactive/JJ
protein/NN
(/(
CRP/NN
)/)
and/CC
interleukin6/IN
(/(
IL6/NN
)/)
in/IN
patients/NNS
with/IN
obesityrelated/VBN
insulin/NN
resistance/NN
(/(
Genco/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Plomgaard/JJ
et/FW
al./FW
,/,
2005/CD
;/:
Pradhan/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
Based/VBN
on/IN
the/DT
identification/NN
of/IN
homeostatic/JJ
regulatory/JJ
mechanisms/NNS
in/IN
the/DT
inflammatory/JJ
system/NN
that/IN
involve/VBP
both/DT
pro/NN
and/CC
antiinflammatory/JJ
cytokines/NNS
,/,
it/PRP
has/VBZ
been/VBN
proposed/VBN
that/IN
antiinflammatory/JJ
cytokines/NNS
,/,
such/JJ
as/IN
insulinlike/JJ
growth/NN
factor1/NN
(/(
IGF1/NN
)/)
,/,
IL10/NN
,/,
IL13/NN
and/CC
IL4/NN
,/,
play/VBP
a/DT
role/NN
in/IN
the/DT
pathogenesis/NN
of/IN
insulin/NN
resistance/NN
and/CC
T2DM/NN
./.
====================
However/RB
,/,
the/DT
underlying/VBG
mechanism/NN
of/IN
their/PRP$
disrupted/VBN
functions/NNS
in/IN
chronic/JJ
inflammation/NN
in/IN
relation/NN
to/TO
T2DM/NN
remains/VBZ
to/TO
be/VB
defined/VBN
./.
====================
Interestingly/RB
,/,
there/EX
has/VBZ
been/VBN
a/DT
report/NN
showing/VBG
disruption/NN
of/IN
antiinflammatory/JJ
responses/NNS
in/IN
type/NN
2/CD
diabetic/JJ
model/NN
animals/NNS
,/,
suggesting/VBG
a/DT
role/NN
of/IN
antiinflammatory/JJ
processes/NNS
in/IN
T2DM/NN
(/(
O'Connor/JJ
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
To/TO
investigate/VB
the/DT
implication/NN
of/IN
anti-inflammatory/JJ
cytokines/NNS
in/IN
the/DT
development/NN
of/IN
T2DM/NN
,/,
we/PRP
conducted/VBD
case-control/JJ
association/NN
studies/NNS
to/TO
examine/VB
the/DT
correlation/NN
between/IN
disease/NN
risk/NN
and/CC
single/JJ
nucleotide/JJ
polymorphisms/NNS
(/(
SNP/NN
)/)
in/IN
the/DT
relevant/JJ
genetic/JJ
loci/NNS
including/VBG
IL4/NN
and/CC
the/DT
IL4/NN
receptor-coding/VBG
gene/NN
,/,
IL4RA/NN
,/,
which/WDT
express/VBP
an/DT
anti-inflammatory/JJ
cytokine/NN
and/CC
its/PRP$
receptor/NN
that/IN
play/VBP
a/DT
key/JJ
role/NN
in/IN
directing/VBG
macrophages/NNS
to/TO
an/DT
'alternatively/RB
activated/VBN
'/``
state/NN
that/IN
is/VBZ
characterized/VBN
by/IN
low/JJ
expression/NN
patterns/NNS
of/IN
pro-inflammatory/JJ
cytokines/NNS
and/CC
high/JJ
levels/NNS
of/IN
anti-inflammatory/JJ
cytokines/NNS
(/(
Gordon/NNP
,/,
2003/CD
)/)
./.
====================
Our/PRP$
findings/NNS
indicate/VBP
that/IN
a/DT
promoter/NN
variant/JJ
of/IN
an/DT
anti-inflammatory/JJ
cytokine/NN
IL4/NN
gene/NN
is/VBZ
associated/VBN
with/IN
risk/NN
of/IN
T2DM/NN
in/IN
the/DT
Korean/JJ
population/NN
,/,
which/WDT
,/,
we/PRP
believe/VBP
,/,
lends/NNS
significant/JJ
insight/NN
into/IN
the/DT
role/NN
of/IN
antiinflammatory/JJ
cytokines/NNS
in/IN
the/DT
T2DM/NN
etiology/NN
./.
====================
Study/NN
subjects/NNS
for/IN
SNP/NN
discovery/RB
and/CC
the/DT
first/JJ
and/CC
second/JJ
stages/NNS
of/IN
association/NN
analyses/NNS
were/VBD
recruited/VBN
from/IN
two/CD
community-based/VBN
cohorts/NNS
established/VBN
as/IN
part/NN
of/IN
the/DT
Korean/JJ
Genome/NN
and/CC
Epidemiology/JJ
Study/NN
(/(
KoGES/NN
)/)
conducted/VBD
by/IN
Korea/NN
Centers/NNS
for/IN
Disease/NN
Control/NN
and/CC
Prevention/NN
(/(
KCDC/NN
)/)
./.
====================
The/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
KCDC/NN
approved/JJ
the/DT
study/NN
,/,
and/CC
informed/VBN
consent/NN
was/VBD
obtained/VBN
from/IN
every/DT
subject/JJ
prior/JJ
to/TO
enrollment/JJ
./.
====================
The/DT
case/NN
subjects/NNS
with/IN
T2DM/NN
were/VBD
selected/VBN
in/IN
accordance/NN
with/IN
the/DT
1999/CD
World/NN
Health/NN
Organization/NN
criterion/NN
./.
====================
Control/NN
subjects/NNS
were/VBD
composed/VBN
of/IN
individuals/NNS
with/IN
no/DT
history/JJ
of/IN
diabetes/NNS
or/CC
firstdegree/JJ
relatives/VBZ
with/IN
diabetes/NNS
,/,
a/DT
fasting/JJ
plasma/NN
glucose/NN
level≤126/NN
mg/dL/NN
and/CC
a/DT
plasma/NN
glucose/NN
level≤140/NN
mg/dL/NN
120/CD
min/NN
after/IN
glucose/NN
ingestion/NN
./.
====================
The/DT
parameters/NNS
measured/VBN
were/VBD
height/RB
,/,
weight/NN
,/,
waist/NN
and/CC
hip/NN
circumference/NN
and/CC
blood/NN
pressure/NN
./.
====================
Body/NN
mass/NN
index/NN
(/(
BMI/NN
)/)
was/VBD
calculated/VBN
by/IN
dividing/VBG
weight/NN
(/(
kg/NN
)/)
by/IN
height/NN
squared/VBD
(/(
m2/NN
)/)
./.
====================
Waisttohip/NN
ratio/NN
(/(
WHR/NN
)/)
was/VBD
calculated/VBN
from/IN
these/DT
measurements/NNS
./.
====================
Blood/NN
samples/NNS
were/VBD
collected/VBN
at/IN
three/CD
separate/JJ
times/NNS
(/(
0/CD
,/,
60/CD
,/,
120/CD
min/NN
)/)
from/IN
the/DT
cohort/JJ
participants/NNS
who/WP
were/VBD
subjected/VBN
to/TO
oral/JJ
glucose/NN
tolerance/NN
tests/NNS
(/(
OGTT/NN
)/)
and/CC
analyzed/VBD
for/IN
glucose/NN
and/CC
insulin/NN
concentration/NN
at/IN
the/DT
given/VBN
time/NN
./.
====================
Cholesterol/NN
,/,
triglyceride/NN
,/,
and/CC
highdensity/JJ
lipoprotein/NN
(/(
HDL/NN
)/)
cholesterol/NN
were/VBD
measured/VBN
at/IN
baseline/NN
./.
====================
Lowdensity/JJ
lipoprotein/NN
(/(
LDL/NN
)/)
cholesterol/NN
level/NN
was/VBD
calculated/VBN
using/VBG
the/DT
Friedewald/JJ
formula/FW
for/IN
subjects/NNS
with/IN
a/DT
triglyceride/NN
level/NN
less/RBR
than/IN
400/CD
mg/dL/NN
(/(
LDL=total/JJ
cholesterol－/NN
(/(
triglyceride//NN
5+HDL/NN
)/)
)/)
./.
====================
Clinical/JJ
parameters/NNS
of/IN
the/DT
study/NN
subjects/NNS
are/VBP
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
To/TO
identify/VB
SNPs/NNS
of/IN
IL4/NN
and/CC
IL4RA/NN
,/,
we/PRP
sequenced/VBD
entire/JJ
exons/NNS
of/IN
the/DT
genes/NNS
including/VBG
the/DT
coding/VBG
and/CC
the/DT
5/CD
’/NN
and/CC
3/CD
’/NN
untranslated/JJ
regions/NNS
(/(
up/IN
to/TO
approximately/RB
2/CD
kb/NN
upstream/RB
of/IN
the/DT
start/NN
codon/NN
and/CC
0.5/CD
kb/NN
downstream/RB
of/IN
the/DT
stop/NN
codon/NN
)/)
as/IN
well/RB
as/IN
exonintron/NN
boundary/RB
regions/NNS
using/VBG
genomic/JJ
DNA/NN
samples/NNS
collected/JJ
from/IN
24/CD
unrelated/JJ
Korean/JJ
subjects/NNS
./.
====================
The/DT
ABI/NN
PRISM/NN
3730/CD
DNA/NN
analyzer/NN
(/(
Applied/VBN
BiosystemsTM/NN
)/)
was/VBD
used/VBN
for/IN
sequencing/NN
and/CC
the/DT
primer/NN
sequences/NNS
were/VBD
designed/VBN
based/VBN
on/IN
GenBank/NN
sequences/NNS
(/(
NG_023252.1/NN
for/IN
IL4/NN
and/CC
NG_/NN
012086/CD
for/IN
IL4RA/NN
)/)
./.
====================
SNPs/NNS
with/IN
a/DT
minor/JJ
allele/NN
frequency≥0.02/NN
and/CC
a/DT
pair-wise/JJ
r2/NN
coefficient≥0.8/CD
were/VBD
selected/VBN
for/IN
further/JJ
genotyping/VBG
./.
====================
The/DT
VeraCode/JJ
GoldenGate/NN
(/(
Illumina/NN
,/,
Inc./NNP
)/)
or/CC
TaqMan®/NN
(/(
Life/NN
technologies/NNS
)/)
genotyping/VBG
assay/NN
was/VBD
employed/VBN
using/VBG
genomic/JJ
DNA/NN
samples/NNS
extracted/VBN
from/IN
blood/NN
of/IN
study/NN
subjects/NNS
./.
====================
Genotypes/NNS
with/IN
concordance/NN
rates≥99/NN
%/NN
and/CC
call/JJ
rates≥98/NN
%/NN
were/VBD
only/RB
included/VBD
for/IN
association/NN
analyses/NNS
./.
====================
Deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
HWE/NN
)/)
was/VBD
tested/VBN
using/VBG
the/DT
χ2/NN
test/NN
./.
====================
We/PRP
examined/VBD
linkage/NN
disequilibrium/NN
(/(
LD/NN
)/)
between/IN
all/DT
pairs/NNS
of/IN
biallelic/JJ
loci/NNS
using/VBG
Lewontin/NN
’/CD
s/NNS
D/NN
’/CD
(/(
|D/NN
’/CD
|/CD
)/)
and/CC
r2/NN
coefficients/NNS
,/,
widely/RB
used/VBN
measures/NNS
for/IN
LD/NN
analysis/NN
./.
====================
Haplotypes/NNS
of/IN
each/DT
individual/JJ
were/VBD
inferred/VBN
using/VBG
HaploView/NN
(/(
Barrett/NN
et/FW
al./FW
,/,
2005/CD
)/)
./.
====================
Logistic/JJ
regression/NN
analyses/NNS
were/VBD
conducted/VBN
to/TO
determine/VB
the/DT
odds/NNS
ratio/NN
(/(
OR/NN
)/)
(/(
95/CD
%/NN
confidence/NN
interval/JJ
(/(
CI/NN
)/)
)/)
for/IN
the/DT
risk/NN
of/IN
T2DM/NN
,/,
controlling/VBG
for/IN
the/DT
covariates/NNS
of/IN
age/NN
,/,
sex/NN
,/,
and/CC
BMI/NN
./.
====================
Multivariate/JJ
linear/JJ
regression/NN
analyses/NNS
were/VBD
performed/VBN
to/TO
test/VB
for/IN
associations/NNS
among/IN
T2DM-related/JJ
intermediate/JJ
phenotypes/NNS
such/JJ
as/IN
BMI/NN
,/,
serum/NN
glucose/NN
and/CC
insulin/NN
level/NN
among/IN
the/DT
unaffected/JJ
group/NN
,/,
controlling/VBG
for/IN
age/NN
and/CC
sex/NN
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
SAS/NN
(/(
SAS/NN
institute/JJ
)/)
./.
====================
The/DT
inverse/JJ
variance/NN
meta-analysis/NN
method/NN
was/VBD
employed/VBN
for/IN
combined/JJ
analysis/NN
of/IN
the/DT
two-stage/JJ
association/NN
study/NN
,/,
assuming/VBG
fixed/JJ
effects/NNS
./.
====================
The/DT
R/NN
program/NN
(/(
version/NN
2.7.1/CD
)/)
was/VBD
used/VBN
for/IN
the/DT
analysis/NN
./.
====================
Heterogeneity/NN
was/VBD
verified/VBN
using/VBG
Cochran/NN
’/CD
s/NNS
Q/NN
test/NN
./.
====================
Gene-gene/NN
interaction/NN
between/IN
the/DT
IL4/NN
and/CC
IL4RA/NN
SNPs/NNS
was/VBD
analyzed/VBN
using/VBG
the/DT
logistic/JJ
regression/NN
method/NN
./.
====================
A/DT
combination/NN
of/IN
the/DT
homozygous/JJ
genotype/NN
of/IN
the/DT
major/JJ
allele/NN
of/IN
both/DT
genes/NNS
(/(
TT/NN
for/IN
rs2243250T＞C/NN
and/CC
CC/NN
for/IN
rs3024610C＞T/NN
)/)
was/VBD
used/VBN
as/IN
a/DT
reference/NN
of/IN
epistasis/NN
./.
====================
Correction/NN
for/IN
multiple/JJ
testing/VBG
was/VBD
conducted/VBN
following/VBG
the/DT
false/NN
discovery/NN
rate/NN
(/(
FDR/NN
)/)
-controlling/JJ
methods/NNS
of/IN
Benjamini/NN
and/CC
Hochberg/NN
./.
====================
The/DT
transcription/NN
factor/NN
binding/NN
of/IN
the/DT
SNPcontaining/JJ
region/NN
was/VBD
analyzed/VBN
using/VBG
FASTSNP/NN
(/(
http/NN
:/:
//fastsnp/JJ
./.
====================
ibms/NNS
./.
====================
sinica/IN
./.
====================
edu/DT
./.
====================
tw/pages/input_CandidateGeneSearch/DT
./.
====================
jsp/RB
)/)
./.
====================
The/DT
genomic/JJ
region/NN
(/(
－433/CD
to/TO
+353/CD
with/IN
respect/NN
to/TO
the/DT
transcription/NN
initiation/NN
site/NN
of/IN
NM_000589/NN
as/IN
+1/CD
)/)
of/IN
IL4/NN
was/VBD
amplified/VBN
using/VBG
standard/JJ
PCR/NN
methods/NNS
./.
====================
DNA/NN
samples/NNS
extracted/VBN
from/IN
rs2243250T/NN
or/CC
rs2243250C/NN
carriers/NNS
were/VBD
used/VBN
as/IN
a/DT
template/NN
for/IN
PCR/NN
./.
====================
Sequences/NNS
of/IN
the/DT
oligonucleotide/NN
primers/NNS
used/VBN
for/IN
amplification/NN
are/VBP
as/IN
follows/VBZ
:/:
5/CD
'/``
to/TO
3/CD
'/``
primer/NN
,/,
CCTGATCACAACATTGCATTTCAGC/NN
;/:
3/CD
'/``
to/TO
5/CD
'/``
primer/NN
,/,
CAGTGACAATGTGAGGCAATTAGTTTATC/NN
./.
====================
Each/DT
PCR/NN
product/NN
was/VBD
thoroughly/RB
sequenced/VBN
prior/JJ
to/TO
insertion/NN
into/IN
the/DT
upstream/JJ
region/NN
of/IN
the/DT
bla/JJ
(/(
M/NN
)/)
reporter/NN
gene/NN
,/,
coding/VBG
for/IN
βlactamase/JJ
(/(
GeneBLAzerTM/NN
,/,
Invitrogen/NN
)/)
,/,
to/TO
ensure/VB
the/DT
SNP/NN
sequence/NN
and/CC
the/DT
proper/JJ
sequence/NN
identity/NN
of/IN
the/DT
constructs/NNS
except/IN
for/IN
the/DT
SNP/NN
of/IN
interest/JJ
./.
====================
Plasmid/NN
DNA/NN
of/IN
the/DT
reporter/NN
constructs/NNS
was/VBD
prepared/VBN
for/IN
transfection/NN
using/VBG
an/DT
endotoxinfree/JJ
DNA/NN
preparation/NN
kit/NN
(/(
Qiagen/NN
)/)
./.
====================
For/IN
transfection/NN
,/,
cells/NNS
of/IN
the/DT
human/JJ
hepatocellular/JJ
carcinoma/NN
cell/NN
line/NN
SNU398/NN
or/CC
the/DT
human/JJ
adipocyte/NN
cell/NN
line/NN
SW872/CD
(/(
3/CD
×104/NN
per/IN
well/RB
)/)
were/VBD
plated/VBN
in/IN
a/DT
blackwalled/JJ
96well/JJ
tissueculture/NN
plate/VBP
with/IN
a/DT
clear/JJ
bottom/IN
(/(
Costar/NN
)/)
./.
====================
After/IN
a/DT
24/CD
hrincubation/NN
period/NN
,/,
the/DT
cells/NNS
were/VBD
transfected/VBN
with/IN
400/CD
ng/NN
of/IN
purified/VBN
reporter/NN
plasmid/NN
DNA/NN
using/VBG
Lipofectamine/JJ
2000/CD
transfection/NN
reagent/JJ
(/(
Invitrogen/NN
)/)
./.
====================
The/DT
reporter/NN
βlactamase/NN
activity/NN
was/VBD
quantitatively/RB
measured/VBN
from/IN
the/DT
transiently/RB
transfected/VBN
cells/NNS
after/IN
48/CD
hrs/NNS
of/IN
incubation/NN
at/IN
37oC/NN
,/,
5/CD
%/NN
CO2/NN
,/,
following/VBG
the/DT
manufacturer/NN
's/POS
instructions/NNS
(/(
Invitrogen/NN
,/,
GeneBLAzerTM/NN
in/IN
vivo/FW
detection/NN
kit/NN
)/)
./.
====================
The/DT
normalized/VBN
activity/NN
was/VBD
presented/VBN
as/IN
a/DT
relative/JJ
ratio/NN
with/IN
respect/NN
to/TO
that/DT
of/IN
cells/NNS
transfected/VBN
without/IN
DNA/NN
./.
====================
To/TO
explore/VB
the/DT
possibility/NN
that/IN
IL4/NN
and/CC
IL4RA/NN
are/VBP
associated/VBN
with/IN
the/DT
risk/NN
of/IN
T2DM/NN
,/,
we/PRP
first/RB
attempted/VBD
to/TO
identify/VB
SNPs/NNS
in/IN
the/DT
Korean/JJ
population/NN
by/IN
sequencing/VBG
the/DT
gene/NN
loci/NNS
including/VBG
5/CD
’/NN
and/CC
3/CD
’/NN
flanking/JJ
regions/NNS
./.
====================
Among/IN
the/DT
identified/VBN
SNPs/NNS
(/(
Supplementary/NN
Fig/NN
./.
====================
and/CC
Supplementary/JJ
Tables/NNS
11/CD
and/CC
12/CD
)/)
,/,
we/PRP
selected/VBD
two/CD
and/CC
eight/CD
SNPs/NNS
from/IN
the/DT
IL4/NN
and/CC
IL4RA/NN
loci/NNS
,/,
respectively/RB
,/,
considering/VBG
LD/NN
and/CC
allele/NN
frequencies/NNS
for/IN
largescale/JJ
genotyping/VBG
./.
====================
We/PRP
genotyped/VBD
474/CD
unrelated/JJ
T2DM/NN
cases/NNS
and/CC
470/CD
nondiabetic/JJ
control/NN
subjects/NNS
to/TO
test/VB
for/IN
association/NN
of/IN
the/DT
polymorphisms/NNS
with/IN
host/NN
susceptibility/NN
to/TO
the/DT
disease/NN
./.
====================
The/DT
subjects/NNS
were/VBD
recruited/VBN
from/IN
Ansan/NN
and/CC
Ansung/JJ
communitybased/VBD
cohorts/NNS
as/IN
part/NN
of/IN
KoGES/NN
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
the/DT
casecontrol/JJ
study/NN
using/VBG
logistic/JJ
regression/NN
analysis/NN
with/IN
adjustment/JJ
for/IN
age/NN
,/,
sex/NN
,/,
and/CC
BMI/NN
,/,
we/PRP
found/VBD
no/DT
differences/NNS
in/IN
the/DT
distribution/NN
of/IN
genotype/JJ
frequencies/NNS
between/IN
the/DT
control/JJ
and/CC
T2DM/NN
cases/NNS
for/IN
any/DT
of/IN
the/DT
SNPs/NNS
tested/VBN
,/,
with/IN
exception/NN
of/IN
a/DT
promoter/NN
variant/JJ
on/IN
the/DT
IL4/NN
locus/NN
,/,
rs2243250T＞C/NN
./.
====================
The/DT
analysis/NN
revealed/VBD
that/IN
the/DT
minor/JJ
allele/NN
C/NN
had/VBD
a/DT
protective/JJ
effect/NN
on/IN
T2DM/NN
risk/NN
compared/VBN
to/TO
that/DT
of/IN
the/DT
major/JJ
allele/NN
T/NN
(/(
protective/JJ
allele/NN
OR=0.70/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.55∼0.89/CD
;/:
p=0.004/NN
(/(
FDRP/NN
＜/CD
0.05/CD
)/)
in/IN
an/DT
additive/JJ
model/NN
,/,
Table/JJ
2/CD
)/)
./.
====================
To/TO
confirm/VB
these/DT
results/NNS
,/,
we/PRP
conducted/VBD
a/DT
second/JJ
stage/NN
case-control/JJ
association/NN
analysis/NN
by/IN
genotyping/VBG
samples/NNS
from/IN
another/DT
community-based/VBN
cohort/NN
,/,
Health/NN
2/CD
of/IN
KoGES/NN
./.
====================
The/DT
genotyping/JJ
of/IN
1,216/CD
cases/NNS
and/CC
1,352/CD
controls/NNS
generated/VBN
additional/JJ
evidence/NN
supporting/VBG
the/DT
association/NN
of/IN
rs2243250T＞C/NN
with/IN
T2DM/NN
(/(
OR=0.80/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.67∼0.94/CD
;/:
p=0.007/RB
(/(
FDR-P＜0.05/NN
)/)
)/)
./.
====================
A/DT
meta/NN
analysis/NN
of/IN
the/DT
data/NNS
of/IN
the/DT
two/CD
cohorts/NNS
produced/VBN
stronger/JJR
combined/VBN
evidence/NN
of/IN
association/NN
(/(
OR=0.77/NN
;/:
95/CD
%/NN
CI/NN
,/,
0.67∼0.88/CD
;/:
p=1.65×10-4/NN
(/(
FDR-P＜0.05/NN
)/)
;/:
Table/JJ
2/CD
)/)
./.
====================
Although/IN
our/PRP$
analyses/NNS
of/IN
individual/JJ
SNPs/NNS
or/CC
haplotypes/NNS
revealed/VBD
no/DT
evidence/NN
of/IN
IL4RA/NN
association/NN
with/IN
T2DM/NN
,/,
the/DT
linear/JJ
regression/NN
analyses/NNS
for/IN
T2DMrelated/JJ
intermediate/JJ
phenotypes/NNS
such/JJ
as/IN
BMI/NN
,/,
WHR/NN
,/,
plasma/NN
glucose/NN
and/CC
insulin/NN
level/NN
in/IN
the/DT
controls/NNS
showed/VBD
modest/IN
association/NN
signals/NNS
of/IN
IL4RA/NN
polymorphisms/NNS
with/IN
BMI/NN
and/CC
insulin/NN
level/NN
in/IN
either/CC
or/CC
both/DT
populations/NNS
(/(
Supplementary/JJ
Table/JJ
2/CD
)/)
./.
====================
This/DT
result/NN
led/VBD
us/PRP
to/TO
examine/VB
the/DT
effect/NN
of/IN
IL4-IL4RA/NN
interaction/NN
on/IN
disease/NN
susceptibility/NN
./.
====================
Logistic/JJ
analysis/NN
for/IN
epistasis/NN
between/IN
rs2243250T＞C/NN
of/IN
IL4/NN
and/CC
the/DT
tagging/JJ
SNPs/NNS
of/IN
IL4RA/NN
(/(
Table/JJ
2/CD
)/)
showed/VBD
existence/NN
of/IN
an/DT
interaction/NN
between/IN
the/DT
IL4/NN
SNPs/NNS
and/CC
an/DT
intronic/JJ
SNP/NN
,/,
rs3024610C＞T/NN
(/(
Table/JJ
3/CD
)/)
./.
====================
The/DT
heterozygous/JJ
genotype/NN
for/IN
rs2243250T＞C/NN
(/(
TC/NN
)/)
and/CC
the/DT
homozygous/JJ
genotype/NN
for/IN
rs3024610C＞T/JJ
(/(
CC/NN
)/)
showed/VBD
significant/JJ
association/NN
with/IN
a/DT
protective/JJ
effect/NN
in/IN
the/DT
first/JJ
stage/NN
,/,
compared/VBN
to/TO
the/DT
TT×CC/NN
as/IN
a/DT
reference/NN
(/(
OR=/NNP
0.40/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.22∼0.73/CD
;/:
p=0.003/RB
)/)
./.
====================
In/IN
the/DT
second/JJ
stage/NN
analysis/NN
,/,
a/DT
combination/NN
of/IN
the/DT
heterozygous/JJ
genotypes/NNS
for/IN
both/DT
SNPs/NNS
(/(
TC×CT/NN
)/)
displayed/VBD
a/DT
moderate/JJ
association/NN
in/IN
the/DT
same/JJ
direction/NN
(/(
OR=0.72/CD
;/:
95/CD
%/NN
CI/NN
,/,
0.5333∼0.98/CD
;/:
p=0.034/RB
)/)
./.
====================
Although/IN
the/DT
same/JJ
combination/NN
of/IN
genotypes/NNS
was/VBD
not/RB
replicated/VBN
,/,
these/DT
results/NNS
suggest/VBP
that/IN
interaction/NN
of/IN
IL4/NN
and/CC
IL4RA/NN
has/VBZ
a/DT
cumulative/JJ
effect/NN
on/IN
T2DM/NN
risk/NN
,/,
compared/VBN
to/TO
the/DT
effects/NNS
from/IN
the/DT
individual/JJ
SNPs/NNS
./.
====================
The/DT
strong/JJ
association/NN
of/IN
rs2243250T＞C/NN
with/IN
T2DM/NN
and/CC
its/PRP$
close/JJ
proximity/NN
to/TO
the/DT
IL4/NN
transcription/NN
initiation/NN
site/NN
(/(
－219/CD
bp/NN
with/IN
respect/NN
to/TO
+1/CD
)/)
led/VBD
us/PRP
to/TO
investigate/VB
the/DT
effect/NN
of/IN
this/DT
polymorphism/NN
on/IN
IL4/NN
promoter/NN
activity/NN
./.
====================
Results/NNS
from/IN
searches/NNS
for/IN
transcription/NN
factor/NN
binding/VBG
sites/NNS
(/(
TFBS/NN
)/)
suggested/VBD
that/IN
rs2243250/NN
C/NN
allele/NN
to/TO
T/NN
allele/NN
alteration/NN
would/MD
generate/VB
a/DT
SOX5/NN
(/(
SRY/NN
(/(
sex/NN
determining/VBG
region/NN
Y/NN
)/)
box/NN
5/CD
)/)
binding/VBG
site/NN
in/IN
the/DT
proximal/JJ
promoter/NN
region/NN
of/IN
the/DT
gene/NN
./.
====================
To/TO
this/DT
end/NN
,/,
we/PRP
prepared/VBD
reporter/NN
gene/NN
constructs/NNS
carrying/VBG
β-lactamasecoding/VBG
sequences/NNS
whose/WP$
expression/NN
was/VBD
controlled/VBN
by/IN
the/DT
IL4/NN
promoter/NN
region/NN
./.
====================
These/DT
reporter/NN
constructs/NNS
were/VBD
then/RB
used/VBN
for/IN
transfection/NN
of/IN
cells/NNS
to/TO
measure/VB
reporter/NN
gene/NN
expression/NN
./.
====================
As/IN
shown/VBN
in/IN
Fig/NN
./.
====================
1/CD
,/,
the/DT
cells/NNS
transiently/RB
expressing/VBG
the/DT
T/NN
allelecarrying/VBG
reporter/NN
gene/NN
showed/VBD
greater/JJR
reporter/NN
activity/NN
than/IN
those/DT
with/IN
the/DT
C/NN
allelecarrying/VBG
construct/NN
,/,
which/WDT
was/VBD
consistent/JJ
with/IN
the/DT
TFBS/NN
prediction/NN
results/NNS
./.
====================
The/DT
allelic/JJ
differential/JJ
expression/NN
was/VBD
consistently/RB
observed/VBN
in/IN
two/CD
different/JJ
cell/NN
lines/NNS
,/,
SW872/NN
,/,
a/DT
human/JJ
adipocyte/NN
cell/NN
line/NN
and/CC
SNU398/NN
,/,
a/DT
human/JJ
hepatocellular/JJ
carcinoma/NN
cell/NN
line/NN
,/,
which/WDT
excluded/VBD
the/DT
possibility/NN
of/IN
cell/NN
linespecific/JJ
indirect/JJ
effects/NNS
./.
====================
This/DT
result/NN
suggests/VBZ
that/IN
the/DT
IL4/NN
promoter/NN
variant/JJ
rs2243250T＞C/NN
might/MD
affect/VB
the/DT
gene/NN
expression/NN
level/NN
by/IN
modulating/VBG
promoter/NN
activity/NN
in/IN
the/DT
SNPcontaining/JJ
region/NN
./.
====================
There/EX
is/VBZ
accumulating/VBG
evidence/NN
indicating/VBG
a/DT
critical/JJ
role/NN
for/IN
subacute/JJ
chronic/JJ
inflammation/NN
in/IN
the/DT
pathogenesis/NN
of/IN
obesityrelated/VBN
insulin/NN
resistance/NN
and/CC
T2DM/NN
(/(
Corvera/NNS
et/FW
al./FW
,/,
2006/CD
;/:
Dandona/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Dandona/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Finegood/RB
,/,
2003/CD
;/:
Genco/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Mangge/NNP
et/FW
al./FW
,/,
2004/CD
;/:
Meerarani/NNP
et/FW
al./FW
,/,
2007/CD
;/:
WangCai/NNP
,/,
2006/CD
;/:
Weisberg/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
In/IN
obesity/NN
,/,
adipose/JJ
tissues/NNS
were/VBD
shown/VBN
to/TO
be/VB
infiltrated/VBN
by/IN
macrophages/NNS
,/,
which/WDT
may/MD
be/VB
a/DT
major/JJ
source/NN
of/IN
locallyproduced/JJ
proinflammatory/JJ
cytokines/NNS
(/(
Weisberg/NN
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
Increased/VBN
levels/NNS
of/IN
TNFα/NN
and/CC
IL6/NN
were/VBD
shown/VBN
to/TO
correlate/VB
with/IN
reduced/VBN
insulin/NN
stimulated/VBN
glucose/NN
uptake/NN
in/IN
obese/DT
and/CC
T2DM/NN
patients/NNS
(/(
Bastard/JJ
et/FW
al./FW
,/,
2006/CD
;/:
Katsuki/NNP
et/FW
al./FW
,/,
1998/CD
;/:
Kern/NN
et/FW
al./FW
,/,
2001/CD
;/:
Mishima/NNP
et/FW
al./FW
,/,
2001/CD
)/)
./.
====================
As/IN
a/DT
homeostatic/JJ
mechanism/NN
in/IN
the/DT
immuneinflammatory/JJ
system/NN
,/,
antiinflammatory/JJ
agents/NNS
including/VBG
IGF/NN
1/CD
,/,
IL10/NN
,/,
IL13/NN
and/CC
IL4/NN
reduce/VBP
secretion/NN
of/IN
proinflammatory/JJ
cytokines/NNS
by/IN
macrophages/NNS
and/CC
stimulate/VBP
the/DT
production/NN
of/IN
various/JJ
antiinflammatory/JJ
molecules/NNS
(/(
Orino/NN
et/FW
al./FW
,/,
1992/CD
;/:
Sone/RB
et/FW
al./FW
,/,
1992/CD
;/:
Vannier/NNP
et/FW
al./FW
,/,
1992/CD
)/)
./.
====================
Several/JJ
reports/NNS
have/VBP
demonstrated/VBN
that/IN
suppression/NN
of/IN
inflammation/NN
by/IN
the/DT
antiinflammatory/JJ
cytokines/NNS
is/VBZ
impaired/JJ
in/IN
T2DM/NN
patients/NNS
(/(
O'Connor/JJ
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
Insulin/NN
resistance/NN
due/JJ
to/TO
obesityrelated/VBN
chronic/JJ
inflammation/NN
has/VBZ
been/VBN
suggested/VBN
as/IN
an/DT
underlying/VBG
mechanism/NN
linking/VBG
antiinflammatory/JJ
cytokine/NN
dysfunction/NN
to/TO
T2DM/NN
(/(
Shoelson/NN
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
IL4/NN
,/,
an/DT
antiinflammatory/JJ
cytokine/NN
,/,
is/VBZ
known/VBN
to/TO
direct/JJ
macrophages/NNS
toward/IN
an/DT
'alternatively/RB
activated/VBN
'/``
state/NN
that/IN
is/VBZ
characterized/VBN
by/IN
low/JJ
expression/NN
patterns/NNS
of/IN
pro/NN
inflammatory/JJ
cytokines/NNS
and/CC
high/JJ
levels/NNS
of/IN
antiinflammatory/JJ
cytokines/NNS
(/(
Gordon/NN
,/,
2003/CD
)/)
./.
====================
Although/IN
its/PRP$
detailed/JJ
mechanism/NN
is/VBZ
not/RB
as/IN
well/RB
defined/VBN
as/IN
that/DT
of/IN
proinflammatory/JJ
cytokines/NNS
,/,
IL4/NN
has/VBZ
received/VBN
much/RB
attention/NN
for/IN
its/PRP$
potential/JJ
relationship/NN
to/TO
insulin/NN
resistance/NN
and/CC
T2DM/NN
,/,
as/IN
supported/VBN
by/IN
an/DT
observation/NN
showing/VBG
that/IN
there/EX
is/VBZ
an/DT
IL4-dependent/JJ
insulin/NN
signaling/VBG
pathway/NN
in/IN
macrophages/NNS
,/,
and/CC
the/DT
positive/JJ
regulatory/JJ
functions/NNS
for/IN
other/JJ
anti-inflammatory/JJ
cytokine/NN
production/NN
mechanisms/NNS
were/VBD
impaired/JJ
in/IN
db/db/JJ
diabetic/JJ
model/NN
mice/NNS
(/(
Hartman/JJ
et/FW
al./FW
,/,
2004/CD
;/:
O'Connor/CC
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
Moreover/RB
,/,
a/DT
recent/JJ
study/NN
clearly/RB
demonstrated/VBD
that/IN
knockout/JJ
mice/NNS
defective/JJ
in/IN
the/DT
IL4-stimulated/JJ
alternative/JJ
activation/NN
of/IN
macrophage/NN
were/VBD
more/RBR
susceptible/JJ
to/TO
obesity/NN
and/CC
insulin/NN
resistance/NN
than/IN
were/VBD
control/JJ
mice/NNS
(/(
Odegaard/JJ
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
These/DT
previous/JJ
results/NNS
prompted/VBD
us/PRP
to/TO
investigate/VB
whether/IN
genetic/JJ
polymorphisms/NNS
of/IN
the/DT
IL4/NN
and/CC
IL4/NN
receptor-coding/VBG
genes/NNS
would/MD
modulate/VB
host/NN
susceptibility/NN
to/TO
T2DM/NN
./.
====================
Although/IN
there/EX
have/VBP
been/VBN
several/JJ
reports/NNS
controversially/RB
linking/VBG
IL4/NN
and/CC
IL4R/NN
polymorphisms/NNS
to/TO
risk/NN
for/IN
autoimmune/JJ
T1DM/NN
in/IN
various/JJ
ethnic/JJ
backgrounds/NNS
,/,
there/EX
have/VBP
been/VBN
no/DT
reports/NNS
such/JJ
an/DT
association/NN
with/IN
T2DM/NN
(/(
Bugawan/NNP
et/FW
al./FW
,/,
2003/CD
;/:
Maier/NNP
et/FW
al./FW
,/,
2005/CD
;/:
Nunez/NNP
et/FW
al./FW
,/,
2008/CD
;/:
Reimsnider/NNP
et/FW
al./FW
,/,
2000/CD
)/)
./.
====================
In/IN
this/DT
report/NN
,/,
we/PRP
present/VBP
results/NNS
from/IN
two-stage/JJ
case-control/JJ
association/NN
and/CC
functional/JJ
analyses/NNS
showing/VBG
that/IN
a/DT
SNP/NN
located/JJ
in/IN
the/DT
IL4/NN
promoter/NN
region/NN
,/,
rs2243250T＞C/NN
,/,
is/VBZ
associated/VBN
with/IN
the/DT
risk/NN
of/IN
T2DM/NN
./.
====================
Although/IN
we/PRP
found/VBD
no/DT
association/NN
of/IN
any/DT
of/IN
the/DT
common/JJ
IL4RA/NN
SNP/NN
with/IN
disease/NN
susceptibility/NN
in/IN
our/PRP$
study/NN
population/NN
,/,
we/PRP
observed/VBD
association/NN
between/IN
intronic/JJ
variants/NNS
of/IN
IL4RA/NN
and/CC
obesity-related/VBN
BMI/NN
and/CC
insulin/NN
level/NN
./.
====================
Moreover/RB
,/,
our/PRP$
gene-gene-interaction/NN
analyses/NNS
implied/VBD
that/DT
this/DT
functional/JJ
IL4/NN
promoter/NN
SNP/NN
could/MD
modify/VB
disease/NN
susceptibility/NN
in/IN
combination/NN
with/IN
the/DT
intronic/JJ
SNP/NN
in/IN
the/DT
IL4RA/NN
gene/NN
./.
====================
Our/PRP$
reporter/NN
gene/NN
expression/NN
assay/NN
indicates/VBZ
that/IN
rs2243250T＞C/NN
may/MD
affect/VB
the/DT
overall/JJ
IL4/NN
promoter/NN
activity/NN
modulating/VBG
the/DT
gene/NN
expression/NN
level/NN
./.
====================
The/DT
minor/JJ
C/NN
allele/NN
,/,
which/WDT
is/VBZ
associated/VBN
with/IN
a/DT
decreased/VBN
risk/NN
of/IN
T2DM/NN
,/,
was/VBD
shown/VBN
to/TO
lower/JJR
the/DT
expression/NN
level/NN
./.
====================
This/DT
functional/JJ
consequence/NN
of/IN
the/DT
protective/JJ
allele/NN
reducing/VBG
IL4/NN
expression/NN
was/VBD
unexpected/JJ
,/,
given/VBN
the/DT
previous/JJ
reports/NNS
showing/VBG
links/NNS
between/IN
impaired/JJ
IL4/NN
function/NN
in/IN
diabetic/JJ
model/NN
animals/NNS
and/CC
obesity/NN
and/CC
insulin/NN
resistance/NN
(/(
Hartman/JJ
et/FW
al./FW
,/,
2004/CD
;/:
O'Connor/CC
et/FW
al./FW
,/,
2007/CD
)/)
./.
====================
A/DT
possible/JJ
explanation/NN
for/IN
our/PRP$
result/NN
is/VBZ
the/DT
presence/NN
of/IN
other/JJ
interacting/VBG
genetic/JJ
and/or/CC
environmental/JJ
effects/NNS
involved/VBN
in/IN
IL4/NN
function/NN
,/,
other/JJ
than/IN
the/DT
expression/NN
level/NN
itself/PRP
./.
====================
It/PRP
could/MD
include/VB
additional/JJ
mechanisms/NNS
by/IN
which/WDT
increased/VBD
expression/NN
levels/NNS
of/IN
IL4/NN
receptor/NN
coding/VBG
gene/NN
and/or/CC
other/JJ
anti-inflammatory/JJ
cytokine/NN
genes/NNS
would/MD
compensate/VB
for/IN
the/DT
decreased/VBN
IL4/NN
expression/NN
level/NN
./.
====================
Additional/JJ
in-depth/IN
functional/JJ
and/CC
physiological/JJ
studies/NNS
will/MD
be/VB
needed/VBN
to/TO
establish/VB
the/DT
mechanism/NN
of/IN
this/DT
association/NN
./.
====================
On/IN
the/DT
basis/NN
of/IN
our/PRP$
findings/NNS
,/,
as/IN
well/RB
as/IN
the/DT
functional/JJ
data/NNS
of/IN
other/JJ
groups/NNS
,/,
we/PRP
propose/VBP
that/IN
the/DT
genetic/JJ
polymorphisms/NNS
of/IN
an/DT
antiinflammatory/JJ
cytokine/NN
coding/VBG
IL4/NN
and/CC
IL4RA/NN
may/MD
modify/VB
an/DT
individual/JJ
's/POS
susceptibility/NN
to/TO
T2DM/NN
./.
====================
Despite/IN
the/DT
recent/JJ
success/NN
of/IN
GWAS/NN
in/IN
identifying/VBG
T2DM/NN
susceptibility/NN
loci/NNS
,/,
our/PRP$
findings/NNS
have/VBP
shown/VBN
that/IN
a/DT
hypothesisbased/JJ
candidate/NN
gene/NN
approach/NN
which/WDT
complements/VBZ
GWAS/NN
is/VBZ
still/RB
a/DT
powerful/JJ
way/NN
to/TO
identify/VB
unknown/JJ
diseaseassociated/JJ
loci/NNS
./.
====================
We/PRP
believe/VBP
our/PRP$
findings/NNS
contribute/VBP
to/TO
a/DT
better/RBR
understanding/NN
of/IN
the/DT
disease/NN
etiology/NN
and/CC
may/MD
help/VB
to/TO
identify/VB
unknown/JJ
genes/NNS
in/IN
the/DT
relevant/JJ
pathways/NNS
or/CC
mechanism/NN
./.
====================
Supplementary/JJ
data/NNS
including/VBG
a/DT
figure/NN
and/CC
two/CD
tables/NNS
can/MD
be/VB
found/VBN
with/IN
this/DT
article/NN
online/JJ
at/IN
http/NN
:/:
//www/JJ
./.
====================
genominfo/RB
./.
====================
org/html/UploadFile/article3_2011306_SP/NN
./.
====================
pdf/IN
./.
====================
This/DT
work/NN
,/,
including/VBG
the/DT
genotype/NN
and/CC
epidemiologic/JJ
data/NNS
,/,
was/VBD
supported/VBN
by/IN
the/DT
Korean/JJ
Genome/NN
Analysis/NN
Project/JJ
(/(
4845301/CD
)/)
and/CC
the/DT
KoGES/NN
(/(
4851302/CD
)/)
,/,
which/WDT
was/VBD
funded/VBN
by/IN
the/DT
Ministry/NN
for/IN
Health/NN
and/CC
Welfare/JJ
,/,
Republic/JJ
of/IN
Korea/NN
./.
====================
We/PRP
appreciate/VBP
Dr./NNP
KyungWon/NN
Hong/JJ
’/CD
s/NNS
helpful/JJ
comments/NNS
on/IN
the/DT
manuscript/NN
and/CC
the/DT
analysis/NN
./.
====================
